Allergen Research Secures $80,000,000 Series B Round

  • Feed Type
  • Date
    3/12/2015
  • Company Name
    Allergen Research
  • Mailing Address
    2000 Alameda de las Pulgas San Mateo, CA 94403 USA
  • Company Description
    Allergen Research Corporation (ARC) develops treatments to protect children with food allergies from the threatening consequences of accidental exposure. ARC was founded in 2011 in partnership with Food Allergy Research & Education (FARE), the nation’s leading nonprofit focused on food allergies.
  • Website
    http://www.allergenresearch.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $80,000,000
  • Transaction Round
    Series B
  • Proceeds Purposes
    ARC will use the proceeds to fund the upcoming Phase 3 clinical trial of ARC’s lead product, AR 101, a standardized, pharmaceutical-grade peanut protein formulation for treating peanut allergy via characterized oral desensitization immunotherapy (CODIT). The company also plans to begin clinical trials for treatment of egg and milk allergies in the coming year.
  • M&A Terms
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor

Trending on Xconomy